Board Member at NurExone Biologic, a publicly traded biopharmaceutical company developing innovative exosome-based regenerative therapies for central nervous system injuries.
Former VP of Finance at V-Wave Ltd., which was acquired by Johnson & Johnson in a transaction valued at up to $1.7 billion.
An experienced finance executive and strategic decision-maker with expertise in financial leadership, M&A and capital markets.